Vertex Pharmaceuticals Reports Robust Third Quarter 2025 Results and Refines Full-Year Outlook as Pipeline Momentum Accelerates Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX), a global leader in genetic and transformative medicine, today…
Genetix Biotherapeutics to Highlight U.S. Gene Therapy Implementation and Patient Experience Data at ASH 2025 Genetix Biotherapeutics Inc. announced that an analysis of recent patient experience data from the U.S.…
PureTech’s Gallop Oncology to Present Promising Phase 1b Data of LYT-200 in Relapsed/Refractory AML at the 2025 ASH Annual Meeting PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the…
DoseMe Expands Precision Dosing Leadership with Strategic Acquisition of Firstline to Deliver Comprehensive Clinical Decision Support in the Global Fight Against Infectious Diseases DoseMe, a global leader in model-informed precision…
Auna S.A. Reports Early Results of Cash Tender Offer and Consent Solicitation for 10.000% Senior Secured Notes Due 2029 Auna S.A. (NYSE: AUNA), a Luxembourg-based public limited liability company and…
Vistagen Completes Phase 3 PALISADE-3 Trial Evaluating Fasedienol for Acute Treatment of Social Anxiety Disorder Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company advancing neuroscience through innovative nose-to-brain therapeutics, announced…
Kyowa Kirin International Appoints Julie Dehaene-Puype as President, Ushering in a New Era of Leadership and Growth Kyowa Kirin International (“KKI”), a regional group company of Kyowa Kirin Co., Ltd.…
Lupin Digital Health Launches VITALYFE™, an AI-Powered Platform to Boost Heart Health for India’s Workforce Lupin Digital Health, India’s leading cardiac digital-therapeutics company, today announced the launch of VITALYFE™, an…
Almost 1/3 Eyeing Job Options Outside US, BioSpace Finds Nearly one-third of biotech and pharma professionals are thinking about leaving the U.S. to find biopharma jobs, according to a BioSpace LinkedIn poll. Career coaches…
FDA Formally Rejects Regeneron’s Eylea HD Over Manufacturing Issues. Despite the rejection, analysts saw Regeneron’s use of an alternate filler for Eylea HD as a positive development, with BMO Capital…
FDA Struggles to Keep Lights On Amid Shutdown as Biopharmas Begin To See Delays While the FDA continues to put out guidance documents and approve drugs, some companies are already…
5 SMID-Cap Pharmas Poised for M&A Action Mergers and acquisitions are not just for Big Pharma. A new report from Leerink Partners takes a stab at identifying the small- to…